The Britain-based drug developer originally expected to start a Phase 3 trial later this year and bring the drug to the market in 2020.
Now, the company must complete a new dose-ranging study, planned for 2017, before advancing to a Phase 3 trial.
Allergy Therapeutics, which specializes in allergy vaccines, will meet with the Food and Drug Administration later this year to discuss the drug.
This is the second allergy drug study to recently run into complications — Chicago-based Circassia Pharamceuticals’ cat allergy treatment failed in a late-stage trial two weeks ago.
More articles on supply chain:
Leukocyte reduction devices recalled for faulty filters
How Britain’s exit from the EU will affect the drug market
Natco Pharma earns FDA approval for ulcer drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
